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Purpose of review 
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent inherited nephropathy. This 
review will focus on the vasopressin and 30 -50 -cyclic adenosine monophosphate (cAMP) signaling pathways 
in ADPKD and will discuss how these insights offer new possibilities for the follow-up and treatment of the 
disease. 
 
Recent findings 
Defective osmoregulation is an early manifestation of ADPKD and originates from both peripheral (renal 
effect of vasopressin) and central (release of vasopressin) components. Copeptin, which is released from 
the vasopressin precursor, may identify ADPKD patients at risk for rapid disease progression. Increased 
levels of cAMP in tubular cells, reflecting modifications in intracellular calcium homeostasis and abnormal 
stimulation of the vasopressin V2 receptor (V2R), play a central role in cystogenesis. Blocking the V2R 
lowers cAMP in cystic tissues, slows renal cystic progression and improves renal function in preclinical 
models. A phase III clinical trial investigating the effect of the V2R antagonist tolvaptan in ADPKD patients 
has shown that this treatment blunts kidney growth, reduces associated symptoms and slows kidney function 
decline when given over 3 years. 
 
Summary 
These advances  open perspectives for the understanding of cystogenesis in ADPKD, the mechanisms of 
osmoregulation, the role of polycystins in the brain, and the pleiotropic action of vasopressin. 
 
Keywords 
collecting duct, osmoregulation, polycystins, V2 receptor antagonist, vasopressin 
 
 
 
 
INTRODUCTION 
Autosomal dominant  polycystic kidney disease 
(ADPKD) is the  most frequent inherited nephrop- 
athy  (prevalence rv1 : 1000), characterized  by  the 
development of multiple cysts  in  the  kidneys. 
Mutations in  PKD1 and PKD2 account for  85  and 
15% of the  affected families, respectively. The PKD1 
and PKD2  genes   encode  integral  membrane 
proteins, polycystin-1 and polycystin-2, which form 
a complex localized in various cellular domains 
including the  primary cilium wherein the  polycys- 
tins  mediate calcium fluxes  in response to mechan- 
ical  or  chemical stimuli. Mutations in  PKD1/PKD2 
alter  intracellular calcium homeostasis and lead  to 
cystogenesis by  increased cell  proliferation, abnor- 
mal  fluid  secretion, and dedifferentiation [1 – 3]. 
The  ADPKD cysts  derive from 1 to 3% of the 
nephrons. The  cysts  may  involve all  nephron  seg- 
ments, but  cysts  of collecting duct origin predom- 
inate [4,5].  Many cysts  likely  develop in utero,  but 
may  only become clinically detectable years  later. 
The  prospective follow-up of ADPKD patients with 
MRI examinations has  established that, in  adults, 
cysts  increase at  ‘an  average’ or  ‘an  average and 
stable’  rate  of approximately 5% per  year  [6]. Total 
kidney volume (TKV) and cyst  volume progression 
are   the    strongest  predictors  of   renal  function 
decline in  ADPKD [7]. More  than 50%  of patients 
with ADPKD  present a  slow  progression to  end- 
stage    renal  failure  that   occurs  usually  in   the 
sixth or  seventh decade. Apart  from symptomatic 
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KEY POINTS 
 
• Defective osmoregulation is an early manifestation of 
ADPKD and originates from both peripheral (resistance 
to vasopressin) and central (impaired release of 
vasopressin) components. 
 
• Copeptin, which is released from the vasopressin 
precursor, may identify ADPKD patients at risk for rapid 
disease progression. 
 
• Increased levels of cAMP in tubular cells, reflecting 
modifications in intracellular calcium homeostasis and 
abnormal stimulation of the vasopressin V2R, play a 
central role in cystogenesis. 
 
• Blocking the V2R lowers cAMP in cystic tissues, slows 
renal cystic progression and improves renal function in 
preclinical models. 
 
• The TEMPO 3:4 phase III clinical trial has shown that 
the V2R antagonist tolvaptan blunts kidney growth, 
reduces associated symptoms and slows kidney 
function decline when given over 3 years in 
ADPKD patients. 
 
 
 
measures, there  is  no   effective treatment  able  to 
slow  disease progression. ADPKD is responsible for 
4 – 10% of the  patients requiring a renal replacement 
therapy. 
The development of cysts in ADPKD requires 
tubular cell proliferation, abnormalities in the extra- 
cellular matrix and transepithelial fluid   secretion 
(Fig.   1).   Increased  concentrations   of   30 -50 -cyclic 
adenosine monophosphate  (cAMP)  play   a  major 
role  in  renal cystic  disease progression [2].  Stimu- 
lation of the  vasopressin V2 receptor (V2R) by the 
antidiuretic hormone arginine vasopressin (AVP) is 
the  major regulator of adenylyl cyclase  activity and 
source of cAMP production in  the  distal nephron. 
Haploinsufficiency in polycystin-1 has  been associ- 
ated  with excessive vasopressin signaling and inap- 
propriate antidiuresis in mouse [8]. Increased levels 
of cAMP and cAMP-target genes  have been observed 
in the  cystic  kidneys of various rodent models. The 
increased cAMP levels  may  arise from decreased 
intracellular Ca2þ   concentration  caused by  muta- 
tions in polycystins, via the  downregulation of 
calcium-dependent phosphodiesterase PDE1 and 
stimulation of the  Ca2þ-inhibitable adenylyl cyclase 
6 (AC6) [2]. In turn, increased cAMP stimulates the 
proliferation and growth of ADPKD cells and drives 
chloride and fluid  secretion (Fig. 1). 
The  importance of the  V2R – cAMP pathway in 
mediating  renal  cystic   disease  has   been  demon- 
strated in animal models of PKD. These  studies 
motivated  a  phase  III  clinical  trial   investigating 
the  effect  of the  selective V2R antagonist tolvaptan 
(OPC-41061) in ADPKD patients [9,10&&]. In this 
review, we will focus on vasopressin and cAMP signal- 
ing  pathways in ADPKD and will discuss how these 
insights offer  new  possibilities for follow-up and 
treatment of the  disease. 
 
 
OSMOREGULATION IN AUTOSOMAL 
DOMINANT POLYCYSTIC KIDNEY 
DISEASE 
That ADPKD is associated with defective osmoregu- 
lation has  been known for  decades. Defective uri- 
nary concentration is frequently observed in ADPKD 
patients and is more severe  in  patients harboring 
large  kidneys on  ultrasound  analysis [11].  A peri- 
pheral resistance to vasopressin has been suggested, 
potentially explained by cystic  lesions affecting the 
interstitial osmotic gradient driving water reabsorp- 
tion [12&]. 
Recently, Ho et al. [13&] investigated the  osmo- 
regulation parameters in adult and pediatric ADPKD 
patients with intact glomerular filtration rate (GFR). 
In  comparison with nonaffected controls, ADPKD 
patients showed a significant defect both in  the 
release of vasopressin in  response to  plasma osmo- 
lality  (central component) and in the  V2R-mediated 
response (nephrogenic component). The peripheral 
resistance to  vasopressin is correlated with TKV as 
assessed by MRI in adults. However, the  presence of 
cysts  or  their number is not a prerequisite for  the 
osmoregulation defect in  ADPKD children [13&]. In 
fact,  developmental studies in diphenlythiazole- 
induced rats  [14]  and cpk  mice   [15]  have shown 
that the  urinary concentrating defect precedes renal 
cyst development. Defective cellular processes have 
been evoked [15], supported by evidence for altered 
vasopressin downstream signaling in  heterozygous 
Pkd1 mice [8]. Although baseline plasma vasopressin 
levels  were similar in ADPKD patients and controls, 
the   relationship between plasma osmolality and 
vasopressin, obtained after  water deprivation,  was 
severely blunted  in  ADPKD  patients. This   obser- 
vation suggests that ADPKD patients have a central 
defect altering the   release of  AVP in  response to 
increased osmolality [13&]. 
The fact that both Pkd1/Pkd2 (mouse) and PKD1/ 
PKD2 (human) are expressed in the  supraoptic, 
suprachiasmatic, and paraventricular nuclei that 
synthesize and release vasopressin could provide a 
basis  for a central osmoregulation defect in ADPKD 
[13&]. The osmosensitivity of vasopressin neurons is 
conferred by mechanosensitive cation channels that 
include TRPV4  [16].  There   is  evidence that  poly- 
cystin-2 interacts with TRPV4 to  form a mechano- 
sensor driving calcium transients in vitro [17].  One 
could hypothesize that  a  defect  in  the complex 
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FIGURE 1. Role of 30 -50 -cyclic adenosine monophosphate (cAMP) in autosomal dominant polycystic kidney disease cyst-lining 
epithelial cells. A cyst-lining tubular cell (from the collecting duct) is depicted, with tight junctions delineating the apical and 
basolateral poles. The complex involving polycystin-1 (PC1) and polycystin-2 (PC2) mediates calcium fluxes in response to 
stimuli sensed by the primary cilium (apical pole). Disruption of the PC1 – PC2 complex is involved in the alteration of 
intracellular Ca2þ  levels. The ADPKD cyst-lining cells show an increased concentration of cAMP, probably reflecting reduced 
intracellular calcium levels [which stimulates Ca2þ-inhibitable adenylyl cyclase (AC) and/or  inhibits the Ca2þ-dependent 
phosphodiesterase  (PDE)] and stimulation of the vasopressin V2 receptor (V2R) pathway. The increased  cAMP levels stimulate 
protein kinase A (PKA)-mediated phosphorylation of various mediators, leading to disruption of flow sensing and 
tubulogenesis; transepithelial fluid secretion driven by the chloride channel cystic fibrosis transmembrane conductance 
regulator (CFTR); increased  expression  of water channels (aquaporin-2, AQP2); and transcriptional regulation of mediators 
involved in cell proliferation. 
 
 
transducing calcium-dependent information in vas- 
opressin neurons could be defective in  ADPKD. 
Alternatively,  the   functional  loss   of   polycystins 
could affect   the   level  of  vasopressin  in  brain, or 
interfere with thirst. 
 
 
VASOPRESSIN AND COPEPTIN IN 
AUTOSOMAL DOMINANT POLYCYSTIC 
KIDNEY  DISEASE 
The    vasotocin – vasopressin  and   the     isotocin – 
mesotocin – oxytocin    lineages   evolved   from   a 
common ancestral molecule when vertebrates and 
invertebrates  diverged from  archemetazoa  about 
500 million years  ago [18,19]. These  extraordinarily 
conserved  peptides  were   recently  shown  to   be 
crucial to  monitor environment and modulate salt 
chemotaxis in Caenorhabditis elegans [20&&]. Vaso- 
pressin and oxytocin act  on  diversified G protein- 
coupled receptors (GPCRs)  that mediate different 
cellular responses in  many tissues (Table  1). Mam- 
mals  have three vasopressin receptors, V1a and V1b 
(coupled to a Gaq protein with phospholipase C 
activation, phosphoinositide hydrolysis and 
calcium   release  as   second   messenger)  and   V2 
(coupled to  a Gas protein with cAMP as second 
messenger). In  addition to  signaling through  acti- 
vation of heterotrimeric G proteins with a, b and g 
subunits, GPCRs also  signal through G protein- 
coupled receptor kinase-mediated phosphorylation 
and b-arrestin binding [21]. Considering the import- 
ance of  vasopressin throughout  evolution, its  role 
in  numerous  cellular functions  (e.g.  proliferation 
and survival; cytoskeletal dynamics, cell adherence 
and migration; centrosomal separation, bipolar 
mitotic spindle formation and planar cell polarity) 
and the  number of downstream signaling pathways, 
its   involvement  in   ADPKD,   beyond  regulation 
 
 
Table  1.  Vasopressin receptor subtypes and functions 
 
 
Subtype 
 
Location 
 
Function 
V1A Vascular smooth muscle Vasoconstriction, myocardial hypertrophy 
 Platelets Platelet aggregation 
 Hepatocytes Glycogenolysis, ureagenesis 
 Myometrium Uterine contraction 
 Vasa recta Decreased blood flow to inner medullaa 
 Medullary interstitial cells Stimulation of prostaglandin synthesisa 
V1B Anterior pituitary gland Releases ACTH, prolactin, endorphins 
V2 Collecting duct Increased water permeability (effect on AQP2)a 
Increased sodium reabsorption (effect on ENaC)a 
  Increased urea permeability (effect on UT-A1)a 
 Thick ascending limb of Henle Increased sodium reabsorptiona 
 Vascular endothelium Releases von Willebrand Factor and Factor VIII 
  Vasodilatation 
ACTH, adrenocorticotropic hormone; AQP2, aquaporin-2; ENaC, epithelial sodium channel; UT-A1, urea transporter A1. 
aContributing to control of water homeostasis. 
 
 
 
of   water  and  solute  transport,  is   not  surpris- 
ing.  Selected signaling pathways and transcription 
factors implicated  in  the   pathophysiology  of 
ADPKD,  downstream  from  vasopressin receptors 
are as follows: 
 
(1)  Gas, cAMP, protein kinase A (PKA), exchange 
protein activated by cAMP, cAMP gated chan- 
nels 
(2)  Gaq, phospholipase C, phosphatidylinositide 
3-kinase (PI3K), protein kinase B (Akt or PKB), 
Ca2þ, Ca2þ/calmodulin-dependent protein 
kinase, calcineurin, nuclear factor of activated 
T-cells  (NFAT) 
(3)  Gbg  canonical and noncanonical signaling 
(4)  G protein-coupled receptor kinase, b-arrestin, 
extracellular signal-regulated kinase 1/2 
(ERK1/2) 
(5) PKA, aquaporin-2, cystic  fibrosis transmem- 
brane conductance regulator (CFTR), urea 
transporter  A1 
(6) RhoA  phosphorylation, Rho  kinase inacti- 
vation, F-actin depolymerization 
(7) Rap1gap,  Raf1,  mitogen-activated  protein 
kinase (MEK), ERK 
(8)  PKA, Ca2þ, PI3K, Akt, B-Raf, MEK, ERK 
(9) Other   mitogen-activated  protein   kinase 
(MAPK) family members [c-Jun  NH2-terminal 
kinase (JNK2), p38a, ERK5] 
(10)   AMP-activated protein  kinase inactivation 
(11)   MAPK, tuberin, Ras homolog enriched in brain, 
mammalian target of rapamycin (mTOR) 
(12)   Glycogen synthase  kinase 3b  (GSK3b),  Wnt, 
b-catenin 
(13)   Bad, Boq,  other apoptosis related proteins 
(14)   Transcription factors [cAMP response element- 
binding protein (CREB), activating protein 1 
(AP1), NFAT, signal transducer and activator of 
transcription 3 (STAT3), Paired box  gene  2 
(Pax2),  etc.] 
 
Vasopressin and oxytocin derive from precur- 
sor  proteins that consist of  a signal peptide, a 
neuropeptide, a Lys-Arg amino acid  cleavage site, 
and  a  neurophysin.  Preprovasopressin addition- 
ally  contains  a  C-terminal  glycoprotein  (or 
copeptin) that follows the  neurophysin sequence. 
The  neuropeptide, neurophysin and copeptin are 
separated during the transport of  secretory gran- 
ules  and secreted in an equimolar ratio. Although 
vasopressin is rapidly cleared from plasma, binds 
to  platelets and  is  unstable ex  vivo,  copeptin is 
stable and has been shown to be  a reliable surro- 
gate    for   circulating   vasopressin  concentration 
[22]. Cross-sectional analyses of ADPKD patients 
[23,24] with  CKD  stage   1 – 4  showed that  serum 
levels  of  copeptin are  associated with markers of 
disease severity and  with  a  decrease in  GFR.  A 
larger, longitudinal study of  251  ADPKD patients 
with CKD  stage   1 – 2  [25&]  showed  a  significant 
association between serum copeptin and changes 
in  kidney volume or  decline in GFR after  adjust- 
ing  for  sex,  age,  cardiovascular risk  factors, diu- 
retic  use,  and baseline TKV. Thus, copeptin  may 
help to  identify ADPKD patients at risk  for  rapid 
disease progression. It should be  noted, however, 
that the  physiological role  of copeptin remains 
unknown. 
 
 
ROLE OF 30 -50-CYCLIC ADENOSINE 
MONOPHOSPHATE IN POLYCYSTIC 
KIDNEY  DISEASE 
Levels of cAMP are consistently elevated in kidneys 
of  animal models of  PKD  [26 – 29,30&&].  Proposed 
mechanisms include: reduction in  intracellular 
calcium due  to disruption of the  polycystins which 
in turn activates calcium inhibitable AC6 and inhi- 
bits  calcium/calmodulin dependent PDE1 (also 
increasing the levels of guanosine-30 ,50 -cyclic mono- 
phosphate, cGMP)  and cGMP inhibitable  PDE3 
[27,31]; dysfunction  of  a  ciliary   protein complex 
which normally constrains cAMP signaling via inhi- 
bition of  AC5/6  activity by  polycystin-2 mediated 
calcium entry and cAMP degradation by  PDE4C 
under the  regulation of  hepatocyte nuclear factor 
1b [32]; depletion of endoplasmic reticulum calcium 
stores that triggers oligomerization and transloca- 
tion of stromal interaction molecule 1 to the  plasma 
membrane wherein it recruits and activates AC6 
[33&];  other  contributory  factors such  as  disrup- 
tion of polycystin-1 binding to  heterotrimeric  G 
proteins, upregulation of V2R, increased levels of 
vasopressin   or   accumulation  of   forskolin,  ATP 
or   other  adenylyl cyclase   agonists  in   cyst   fluid 
[34 – 37]. A recent study showing marked inhibition 
of cystogenesis in a conditional Pkd1 model has 
confirmed the  importance of AC6 in the  pathogen- 
esis of ADPKD [38]. 
The   upregulation  of  cAMP  signaling  plays   a 
central  role   in   the   pathophysiology  of   ADPKD 
mainly through activation of PKA and downstream 
effectors (Fig.  1).  PKA activates the  CFTR channel 
and stimulates chloride and fluid  secretion [39,40]. 
Under normal conditions, activation of PKA inhibits 
mitogen-activated protein kinase (MAPK) signaling 
and cell  proliferation. However, in  PKD or  in  con- 
ditions wherein intracellular calcium is reduced, 
PKA activates  MAPK  kinase  (MEK)  in  a  Src,  Ras 
and B-raf-dependent manner. MEK in  turn phos- 
phorylates and activates MAPK, also known as extra- 
cellular signal-regulated  kinase (ERK) [41,42].  Src 
and ERK also  mediate downstream signaling from 
b-arrestin and from growth factors and their recep- 
tor  tyrosine kinases that are upregulated in ADPKD 
[43].  Therefore, GPCR and receptor tyrosine kinase 
signaling converge in the  activation of c-Src, a non- 
receptor tyrosine kinase. In  the  setting of reduced 
intracellular calcium, PKA also  activates CREB sig- 
naling and, downstream from ERK and CREB, AP1 
that upregulates amphiregulin and other EGF like 
factors that further promote growth [44]. PKA is also 
implicated in  activation of  mTOR  (via  ERK-medi- 
ated  phosphorylation of tuberin) [45,46] and Wnt – 
b-catenin signaling (via phosphorylation of GSK3b 
and   b-catenin)   [47,48].  Also,    PKA   activation 
interferes  with   Wnt   dependent   tubulogenesis 
[49&],  increases ciliary  length [50],  leads  to  centro- 
somal amplification  [51],  and  upregulates STAT3 
[52]  and possibly Pax2  signaling [53&],  all  features 
observed in PKD. Through these multiple pathways, 
upregulation of  cAMP  and PKA signaling  triggers 
cell  proliferation and apoptosis, enhances fluid 
secretion, disrupts the  control of tubular diameter, 
and induces cystogenesis. 
 
 
RATIONALE  FOR V2 RECEPTOR 
ANTAGONISM IN AUTOSOMAL 
DOMINANT POLYCYSTIC KIDNEY 
DISEASE 
Given its central role,  there is a strong rationale to 
lower  cAMP in  cystic  tissues. Blocking the effect  of 
vasopressin on  V2R is particularly appealing: V2R 
are  almost exclusively located on  collecting ducts, 
connecting  tubules, and thick ascending limbs of 
Henle [54,55], the  main sites  of cystogenesis, thus 
minimizing  off-target toxicities. Vasopressin is the 
major GPCR  responsible for  cAMP  generation in 
isolated collecting ducts [56].  The  kidneys are con- 
tinuously exposed to the  tonic action of vasopressin 
to  avoid dehydration. This  exposure is further 
enhanced in PKD, with defective intracellular proc- 
esses causing cAMP generation and PKA activation 
(see above). 
V2R  antagonists (mozavaptan and/or  tolvap- 
tan) attenuate the  progression of PKD in  cpk  mice 
[15]  and in   rodent  models of  nephronophthisis 
( pcy  mouse)  [27],   ARPKD  (PCK  rat)   [27,57]   and 
ADPKD-2 (Pkd2-/WS25   mouse) [58].  Mozavaptan  is 
also effective in a conditional Pkd1 knockout when 
treatment is  started early  following gene  deletion 
[59].   Suppression  of   vasopressin  by   high  water 
intake sufficient to achieve a  3.5-fold increase in 
urine output attenuates the  progression of PKD in 
the  PCK rat [60]. Cyst development is markedly 
inhibited in PCK rats lacking circulating vasopressin 
(generated  by   crosses    of   PCK   and  Brattleboro 
rats),   whereas administration  of  the   V2R  agonist 
1-deamino-8-d-arginine   vasopressin  fully   rescues 
the  cystic  phenotype [61]. Low concentrations of 
tolvaptan also inhibit vasopressin-induced chloride 
secretion  and  decrease  in-vitro  cyst   growth  of 
human ADPKD cells [62]. 
 
 
CLINICAL  TRIALS OF V2 RECEPTOR 
ANTAGONISTS IN AUTOSOMAL 
DOMINANT POLYCYSTIC KIDNEY 
DISEASE 
Small clinical trials were initially conducted to ascer- 
tain the safety and pharmacokinetics of tolvaptan in 
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FIGURE 2. Tolerability and efficacy during titration phase with tolvaptan. In the initial 2 months of the TEMPO 2:4  study a 
split-dose regimen of oral tolvaptan (8 a.m./4  p.m.) was up titrated (15/15, 30/15, 45/15, 60/30, 90/30 mg/d) until 
tolerability was reached. Tolerability was defined as self-reported tolerance of a specific dose regimen by responding yes to 
the question: ‘could you tolerate taking this dose of tolvaptan for the rest of your life?’ Efficacy was defined by the capacity to 
suppress the action of vasopressin on the kidney reflected by sustained urine hypotonicity (Uosm <300 mOsm/kg). 
Reproduced with permission from [64]. 
 
 
adult patients with ADPKD [63]. Twice daily  admin- 
istration is  necessary to block   V2R  activation 
throughout a 24 h period as reflected by urine hypo- 
tonicity. A phase 2, open-label, uncontrolled, 3-year 
clinical trial  evaluated the  long-term safety  and 
tolerability of  tolvaptan in  ADPKD  [64].  Patients 
were  randomized to  one  of  two  doses  (45/15 and 
60/30 mg)  chosen after  an  analysis of efficacy  and 
self-reported tolerability during  titration  (Fig.  2). 
Adverse  events were  mainly related to aquaresis. 
Twelve  (19%)  patients withdrew from the study, in 
six cases  due  to  adverse events. Changes in  TKV 
(determined  by   MRI)  and  eGFR  were   compared 
with historical controls from the CRISP and the 
Modification of Diet in Renal Disease studies. Kidney 
volume increased 5.8 versus  1.7 %/year and annual- 
ized  eGFR declined -2.1  versus   -0.71 ml/min per 
1.73 m2   per   year.   Limitations  of  the   study  were 
the small  number of  patients and the  utilization 
of noncontemporary controls with unmatched 
ethnicities. 
Slight  elevations in serum creatinine, rapidly 
reversible  after   cessation  of  drug   administration, 
were  observed in phase 2 clinical trials  with tolvap- 
tan. The short effects  of tolvaptan were investigated 
in  20 ADPKD patients before and after  a split-dose 
for 1 week [65]. Tolvaptan induced aquaresis was 
accompanied by significant reduction in iothala- 
mate clearance, increase in  serum uric  acid  due  to 
decreased  uric   acid   clearance, and  reduction in 
serum potassium, without change in  renal blood 
flow.  Post-hoc analysis of renal MRIs showed that 
tolvaptan  induced  a   3.1%   reduction  in   kidney 
volume and in  the  volume of individual cysts. 
The  results of a phase 3, multicenter, random- 
ized,  double-blind, placebo-controlled, parallel-arm 
trial  of tolvaptan in ADPKD (TEMPO, Tolvaptan 
Efficacy,   and  Safety   in   Management  of   ADPKD 
and its  Outcomes, 3:4),  conducted at  129  sites  in 
15 countries, have been recently published [9,10&&]. 
ADPKD patients (n ¼ 1445)  with rapid disease pro- 
gression  reflected  by  kidney  volumes  of  at  least 
750 ml at age between 18 and 50 years, but  still with 
preserved renal function (eCrCl  >60 ml/min), were 
randomized 2  to  1  to  tolvaptan or  placebo. Split 
45/15 mg doses of study drug  were titrated at weekly 
intervals to  60/30 and 90/30 mg,  if tolerated. The 
maximally  tolerated   dose    was   maintained   for 
3 years. Serum creatinine and laboratory parameters 
were measured every 4 months and renal MRIs were 
obtained  yearly. Participants were  instructed to 
drink enough water to prevent thirst. Twenty-three 
percent of tolvaptan-treated patients withdrew from 
the  trial,  15% due  to adverse events including aqua- 
resis-related symptoms in 8%.  The  corresponding 
percentages in  the   placebo group were  14,  5  and 
0.4%.   Of  the   patients  randomized  to   tolvaptan 
who completed the  3 years  of treatment, 55%  were 
tolerating the  highest dose. 
The  analysis of  the primary endpoint  showed 
that tolvaptan reduced the  rate  of kidney growth by 
50%,  from 5.5  to  2.8%  per  year  (Fig. 3). The  treat- 
ment effect  of tolvaptan was greatest from baseline 
to year one, but  it was also significant from year 1 to 
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FIGURE 3. Effect of tolvaptan on total kidney volume in autosomal dominant polycystic kidney disease. (a) The slopes of the 
growth in total kidney volume in the intention-to-treat population during the 3-year treatment period; tolvaptan reduced the rate 
of kidney growth from 5.5 to 2.8% per year (P < 0.001).  (b) The treatment effect of tolvaptan was greatest from baseline to 
year one, but it was also significant from year 1 to 2, and from year 3 to 4, resulting in an increasing separation in kidney 
volume over time. Reproduced with permission from [10&&]. 
 
 
2, and from year  3 to 4 (Fig. 3). The  analysis of the 
key composite secondary endpoint of time to devel- 
opment or  progression of  multiple clinical events 
(worsening kidney function, severe  kidney pain, 
hypertension, and albuminuria) showed fewer 
clinical events for tolvaptan compared with placebo, 
with a hazard ratio of 0.87.  This  positive result was 
driven by favorable effects  on  kidney pain and kid- 
ney  function decline (Fig. 4). The administration of 
tolvaptan was associated with a 61%  lower  risk of a 
25% reduction in reciprocal serum creatinine and a 
36% lower risk of kidney pain. The administration of 
tolvaptan also  reduced the  rate  of decline of recip- 
rocal  serum creatinine, from 3.81  to  2.61  per  year 
(Fig. 4). 
The frequencies of adverse events were similar in 
both  groups. Adverse   events related to  aquaresis 
were    more  common   with   tolvaptan,   whereas 
adverse events related to ADPKD (kidney pain, hem- 
aturia, and urinary tract infection) were  more com- 
mon with placebo. Increases in  serum sodium and 
uric  acid  were  more frequent with tolvaptan. 
Tolvaptan-treated patients had more frequent 
elevations of  liver  enzymes, which led  to  discon- 
tinuation of the  drug  in  1.8%. 
At the present time tolvaptan is not approved 
for  the indication of  ADPKD and should not be 
administered to these patients outside of an 
approved research study. The  value   of  tolvaptan 
as  a  long-term treatment in ADPKD will  depend 
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FIGURE 4. Effects of tolvaptan on secondary endpoints and change in kidney function. (a) Hazard ratios for the secondary 
end point of autosomal dominant polycystic kidney disease (ADPKD)-related events with tolvaptan as compared with placebo 
for the secondary composite end point and its component events. (b) The slopes of kidney function were estimated with the use 
of the reciprocal of the serum creatinine level in the intention-to-treat population during the treatment period. The administration 
of tolvaptan also reduced the on treatment rate of decline of reciprocal serum creatinine, from 3.81 to 2.61 per year 
(P < 0.001). Reproduced with permission from [10&&]. 
 
 
on the balance between benefits and risks. Polyuria, 
thirst and related adverse events may  impact the 
ability of some patients to tolerate effective doses. 
Patients taking tolvaptan should have easy access to 
and be  able   to  tolerate water. Levels  of  plasma 
sodium and uric  acid  require monitoring. Liver 
function should be  monitored  closely during 
therapy. Patients in TEMPO 3:4 had relatively pre- 
served renal function.  Efficacy  in  more advanced 
stages of the  disease has not been thoroughly ascer- 
tained. 
 
 
ALTERNATIVE APPROACHES TO TARGET 
30-50 -CYCLIC ADENOSINE 
MONOPHOSPHATE 
A number of GPCRs, in addition to V2R, may  affect 
the generation of cAMP and potentially cystogenesis 
 
 
in  ADPKD. Somatostatin receptors and to  a  lesser 
extent secretin, prostaglandin E2 (PGE2), and puri- 
nergic receptors have received attention.  Somato- 
statin acts  on   five  GiPCRs  (SSTR1 – 5)  present on 
renal tubular epithelial cells  [66].  As somatostatin 
has  a half-life of approximately 3 min, more stable 
synthetic peptides (octreotide, lanreotide, and pasir- 
eotide) have been developed for clinical use. Octreo- 
tide  and lanreotide bind to  SSTR2 and SSTR3, 
whereas pasireotide has  high affinity for  SSTR1 – 3 
and SSTR5. In  preclinical studies, octreotide and 
pasireotide halt the  expansion of hepatic cysts from 
PCK rats  in vitro and in vivo [67,68]. Similar  effects 
were observed in the  kidneys. Three  randomized, 
placebo-controlled studies of  octreotide or  lanreo- 
tide   have  been  completed  [69 – 74].   These   drugs 
induce  small, but   significant and  sustained, 
reductions in liver volume associated with improved 
perception of  bodily pain  and  physical activity, 
and slow  kidney growth at least  during the   first 
year  of treatment. Additional clinical trials for 
ADPKD  and for  polycystic  liver   disease  are  cur- 
rently active. 
Secretin acting on its Gs-coupled receptor stimu- 
lates  urine concentration in wildtype and vasopres- 
sin-deficient   Brattleboro   rats    at    pharmacologic 
doses  [75&]. However, administration  of exogenous 
secretin to PCK or Pkd2-/WS25 mice  and genetic 
elimination of  the  secretin receptor in  Pkd2-/WS25 
mice  had no detectable benefit on the  development 
of polycystic kidney or liver disease [75&]. Therefore, 
it seems  unlikely that secretin receptor blockers 
would be valuable to  treat ADPKD. 
Of  the four  PGE2  specific E-prostanoid  recep- 
tors,  E-prostanoid 2, and E-prostanoid 4 are coupled 
to Gas and E-prostanoid 3 to Gai proteins [76]. PGE2 
stimulates  cell  proliferation,  fluid   secretion, and 
in-vitro  cystogenesis  via   preferentially  expressed 
E-prostanoid 2 in human ADPKD cells [77], whereas 
it exerts similar effects via preferentially expressed E- 
prostanoid 4  in  IMCD-3   cells  [78].  In  a  different 
study, however, PGE2-stimulated proliferation and 
fluid    secretion  by   ADPKD-1   cultured  epithelial 
cells   via   activation  of   E-prostanoid  4   receptors 
[79].  E-prostanoid 1, which is coupled to  Gaq and 
calcium mobilization, promotes vasopressin syn- 
thesis in the  hypothalamus [80]. Whether E-prosta- 
noid 2 or E-prostanoid 4 antagonists or E-prostanoid 
3 or E-prostanoid 1 agonists affect the  development 
of PKD in vivo has  not been investigated. 
Purinergic receptors encompass adenosine sen- 
sitive  P1 and ATP sensitive P2 receptors. Two P1 
receptors (A1 and A3) are  coupled to  Gai proteins 
and two  (A2a  and A2b)  to  Gas proteins. Possibly 
driven by NF-kB activation, A3 receptor is expressed 
at high levels in ADPKD compared with normal renal 
tissues. The  A3 agonist 2-chloro-N6-(3-iodobenzyl)- 
adenosine-50 -N-methyluronamide    lowers     cAMP, 
ERK, and mTOR  activation and cell proliferation in 
ADPKD derived and in  PC1-deficient HEK293  cells 
[81].  The  P2Y receptors are  GPCRs,  enhance cAMP 
production through receptor-mediated prostaglan- 
din release, and are  upregulated in  kidneys of a rat 
model of ADPKD. Nonspecific P2Y receptor inhibi- 
tors  (reactive blue   2  and suramin) and the   P2Y1- 
specific antagonist  MRS2179  inhibit MDCK  cyst 
growth in collagen matrices [82]. The P2X receptors 
are ATP-gated, calcium-permeable cation channels. A 
potential role of P2X7 is suggested by the inhibition 
of  cystogenesis by  the antagonist OxATP  in  pkd2 
zebrafish morphants [83]. 
 
 
HIGH WATER INTAKE IN AUTOSOMAL 
DOMINANT POLYCYSTIC KIDNEY 
DISEASE 
On the  basis of the  role of cAMP in cyst progression, 
the  ingestion of supplemental water is increasingly 
considered as a potential treatment for ADPKD [84]. 
Provided it  can  be  consistent and sustained, high 
water intake would suppress endogenous vasopres- 
sin,  lower  stimulation of V2R, and decrease cAMP 
levels  in cyst-lining cells. Low endogenous vaso- 
pressin  would,  thus,  reduce  nonspecific  effects 
(V1a  and V1b-mediated) caused by  increased 
endogenous  vasopressin associated with  chronic 
use of selective V2R antagonists [85]. A normal 
capacity to dilute urine has been observed in ADPKD 
patients with preserved eGFR, suggesting that rapid 
inhibition of vasopressin release is preserved 
[13&,86,87]. The  importance of dietary sodium and 
protein intake to ensure free-water excretion should 
be  emphasized [84].  The  relevance of  high water 
intake in  ADPKD has  been substantiated by an  ele- 
gant study showing that high water intake for  10 
weeks  in the  PCK rat  reduced vasopressin as well as 
the  renal expression of V2R and the  cAMP-depend- 
ent  activation of the  MAPK/ERK kinase (MEK)/ERK 
pathway through the intermediacy of B-Raf, a kinase 
that phosphorylates and activates MEK [60].  These 
changes were reflected by a approximately 30% 
decrease in kidney/body weight ratio and by 
improved renal function. 
Recommendations for intake of water in ADPKD 
based   on   preclinical studies have been  proposed 
[84].  High  water intake (approx. 3 l/day), sufficient 
to achieve a low urinary osmolality (<250 mOsm/kg 
H2O), can  be proposed in  ADPKD patients with an 
eGFR   more  than  30 ml/min.   Exclusions  would 
include patients on severe protein or sodium restric- 
tion; those with volume contraction; those taking 
diuretics or drugs enhancing the  release of AVP; or 
 
  
those presenting abnormal voiding problems. 
Monitoring  plasma  sodium  should  be   advised. 
The intake should be that of nonmineralized water, 
with no  addition of sugar  and no caffeine. Patients 
should split   the   intake during the daytime, and 
void frequently. Urine osmolality remains essential 
to  monitor the action of vasopressin, as urinary 
cAMP levels  showed no  predictive value [86]. High 
water intake should not be advised to patients with 
more advanced CKD (eGFR <30 ml/min). Limita- 
tions of high water intake include risk of hypona- 
tremia and poor compliance, as thirst is not driving 
the  fluid  intake like in diabetes insipidus or V2R 
inhibition. 
 
 
CONCLUSION 
Defective urinary concentration  is  one   the   first 
clinical manifestation  of  ADPKD.  The  association 
of  ADPKD  with impaired osmoregulation has 
recently been completed  by  cellular, animal and 
clinical studies, indicating that  vasopressin and 
upregulation of cAMP signaling play  a central role 
in cystogenesis. For the  first time, a treatment using 
a  V2R  antagonist was  shown to  be  able  to  slow 
kidney growth, with potential benefits on  the  func- 
tional and symptomatic progression in  ADPKD 
patients. These advances open exciting perspectives, 
not only for the  understanding of cystogenesis and 
cyst  progression in ADPKD, but  also  for more basic 
questions related to  the  components of osmoregu- 
lation, the   role   of  polycystins  in   the   brain, the 
cellular  pathways  regulated  by   vasopressin and 
cAMP, and the  pleiotropic action of vasopressin. 
Burning clinical questions are  open: which group 
of patients, and what stage  of disease would benefit 
most from the  V2R antagonist? What are the  value 
and potential role of copeptin as a marker of disease 
progression? What is  the   optimal extent of  vaso- 
pressin inhibition  to  slow  ADPKD  –  and for  how 
long this  should be maintained? The  extent and 
consequences of increased endogenous vasopressin 
levels  in  cases  of chronic V2R inhibition should be 
assessed, as  well  as  the  potential  psychologic and 
social  consequences of  polyuria, nycturia, or  high 
water intake. Answering these questions will  be 
critical to  tailor interventions capable to  prevent 
decline of renal function and improve clinically 
significant outcomes in  ADPKD. 
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